Rich McAvoy named Chief Business Officer at Avid. Read the Release
Rich McAvoy named Chief Business Officer at Avid. Read the Release
From groundbreaking presentations to dynamic panel discussions and expert-led roundtables, this event offers you invaluable insights into the challenges and opportunities across the gene therapy landscape. Whether it’s overcoming clinical trial complexities, navigating evolving regulatory requirements, or optimizing manufacturing scalability, this summit equips you with the knowledge needed to mitigate risks, avoid costly setbacks, and accelerate your gene therapy pipeline.
Gene Therapy Development Summit
March 25, 2025 - March 27, 2025
Related Events
Seasoned business and finance leader brings growth mindset to support Avid’s next phase expansion and client execution TUSTIN, Calif. — [January 15, 2026] — Avid Bioservices, a leading contract development […]
Read moreThe newly created role marks a major step in CEO Kenneth Bilenberg’s vision to scale Avid for its next chapter of growth. TUSTIN, Calif., November 10, 2025 – Avid […]
Read moreTustin, CA, USA – September 15, 2025 – Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kenneth Bilenberg as its new […]
Read moreSOUTH SAN FRANCISCO, California – August 05, 2025 – Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical […]
Read moreDownload PDF Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completed GHO […]
Read moreDownload PDFAvid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger TUSTIN, Calif., February 5, 2025 — Avid […]
Read more